{"id":48545,"date":"2022-09-19T17:01:51","date_gmt":"2022-09-19T15:01:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-vacuum-assisted-breast-biopsy-device-market-report-2022-increased-prevalence-of-breast-cancer-to-drive-growth-researchandmarkets-com\/"},"modified":"2022-09-19T17:01:51","modified_gmt":"2022-09-19T15:01:51","slug":"global-vacuum-assisted-breast-biopsy-device-market-report-2022-increased-prevalence-of-breast-cancer-to-drive-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-vacuum-assisted-breast-biopsy-device-market-report-2022-increased-prevalence-of-breast-cancer-to-drive-growth-researchandmarkets-com\/","title":{"rendered":"Global Vacuum-Assisted Breast Biopsy Device Market Report 2022: Increased Prevalence of Breast Cancer to Drive Growth – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Vacuum-Assisted Breast Biopsy Device Market, By Procedure, By Product, By Type, By Technique, By End User & By Region – Forecast and Analysis 2022-2028”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nGlobal vacuum-assisted breast biopsy device market was valued at US$ 244.96 million in 2021, and it is expected to reach a value of US$ 334.31 million by 2028, at a CAGR of 4.5% over the forecast period (2022 – 2028).\n<\/p>\n

\nThe increased prevalence of breast cancer is propelling the vacuum-assisted breast biopsy market forward. Vacuum-assisted breast biopsy (VABB) devices are gaining popularity over traditional biopsy methods due to their ability to obtain large amounts of tissues with contiguous specimens, the ability to obtain multiple specimens with a single needle insertion, a more accurate diagnosis with a lower cancer miss rate, and lower histological underestimates.\n<\/p>\n

\nTop-down and bottom-up approaches were used to estimate and validate the size of the Global vacuum-assisted breast biopsy device market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details:\n<\/p>\n

\nSegments covered in this report<\/strong>\n<\/p>\n

\nThe Global vacuum-assisted breast biopsy device market is segmented by procedure, by product, by type, by technique, by end user. Based on procedure, the market is categorized into Tethered, Untethered.\n<\/p>\n

\nBased on product, the market is categorized into Vacuum-Assisted Biopsy Systems, Vacuum-Assisted Biopsy Needles. Based on type, the market is categorized into 9-12G, < 9G, < 12G.\n<\/p>\n

\nBased on technique, the market is categorized into Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, MRI-Guided Biopsy, Others.\n<\/p>\n

\nBased on end user, the market is categorized into Hospitals, Academic, Research Institutes, Diagnostic, Imaging Centers, Others. By region, the global vacuum-assisted breast biopsy device market is categorized into North America, Europe, Asia-Pacific, South America, and Middle East & Africa.\n<\/p>\n

\nDriver<\/strong>\n<\/p>\n

\nVacuum-assisted breast biopsy (VABB) devices are gaining popularity over traditional biopsy methods due to their ability to obtain a large number of tissues with contiguous specimens, the ability to acquire multiple specimens with a single needle insertion, a more accurate diagnosis with a lower cancer miss rate, and lower histological underestimates.\n<\/p>\n

\nAside from diagnostic reasons, VABB is also a known means of therapeutic excision of benign tumors such as fibroadenomas. The use of percutaneous VABB can reduce the need for open surgical biopsy or excision, as well as the costs of operating room or hospital stays associated with surgical excision. As a result, all of these considerations are propelling the adoption of vacuum-assisted breast biopsy (VABB) equipment.\n<\/p>\n

\nRestraint<\/strong>\n<\/p>\n

\nVABB has a greater initial cost, such as vacuum generators and biopsy hand-pieces, as well as a higher ongoing cost of consumables such as needles, tubing, and localizing markers. VABB is frequently utilized as a second line of biopsy in some hospitals and research facilities due to its higher cost when compared to fine needle aspiration (FNA) biopsy or core biopsy. In such cases, VABB is only performed after insufficient or inconclusive cytology or histology, or when previous FNA or core biopsies produced contradictory imaging-pathology results.\n<\/p>\n

\nMarket Trends<\/strong>\n<\/p>\n

\nThe vacuum-assisted breast biopsy equipment market is expanding as a consequence of a robust research environment that has helped to the development of more accurate and least invasive therapies for breast cancer diagnosis. Governments have also made efforts to foster a stable and all-encompassing environment for cancer research, which has benefited in the development of these diagnostic instruments.\n<\/p>\n

\nKey Topics Covered:<\/strong>\n<\/p>\n

\nExecutive Summary<\/strong>\n<\/p>\n

\nMarket overview<\/strong>\n<\/p>\n

\nParent Market Analysis<\/strong>\n<\/p>\n

\nMarket overview<\/strong>\n<\/p>\n

\nMarket size<\/strong>\n<\/p>\n

\nKey Market Insights<\/strong>\n<\/p>\n